The oncolytic viral immunotherapy ASP1012 optimizes memory T-cell responses after systemic delivery.

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Clinical application of oncolytic viral immunotherapies (OVIs) is limited by intratumoral delivery requirements and variable efficacy.
• Pre-existing anti-viral immunity can also impede OVI effectiveness.

Purpose of the Study:

• To develop a novel OVI, ASP1012, with improved systemic delivery and enhanced therapeutic activity.
• To overcome limitations of current OVIs for broader clinical applicability.

Main Methods:

• Engineered a vaccinia virus strain (ASP1012) to express chemokine receptor CCR2 for enhanced lymphocyte targeting.
• Incorporated a Leptin-IL2 fusion protein to augment T-cell activation and modify the tumor microenvironment.
• Evaluated ASP1012's efficacy in multiple mouse tumor models following intravenous administration.

Main Results:

• ASP1012 demonstrated improved systemic delivery, even with pre-existing anti-viral immunity.
• Expression of CCR2 facilitated virus redirection to tumors via infected lymphocytes.
• Leptin-IL2 fusion protein significantly enhanced T-cell activation and therapeutic outcomes.
• Complete tumor responses were achieved in multiple mouse models after intravenous delivery of ASP1012.

Conclusions:

• ASP1012 represents a promising advancement in OVI, overcoming key delivery and efficacy challenges.
• The dual-action strategy of enhanced targeting and potent immune stimulation offers a new therapeutic paradigm for solid tumors.